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Littlehasbeen writtenaboutacutebloodlossfromhemodialysisvascularaccess.Wedescribe a57-year-old Caucasianmalewithan
approximately 7gm/dL drop in hemoglobin due to bleeding from a ruptured aneurysm in his right brachiocephalic arteriovenous
ﬁstula(AVF).There wasno evidence ofﬁstula infection.Thepatient wassuccessfully managedby blood transfusionsandinsertion
of a tunneled dialysis catheter for dialysis access. Later, the ﬁstula was ligated and a new ﬁstula was constructed in the opposite
arm. Aneurysm should be considered in cases of acute vascular access bleeding in chronic dialysis patients.
1.Introduction
Acute blood loss through vascular access can be a life
threatening problem. The case under discussion highlights
the importance of vascular access monitoring and surveil-
lance to prevent failure. Blood loss through AVF can be
from aneurysms, stenosis and subsequent rupture, infection,
trauma, suicide and, use of anticoagulants and antiplatelet
drugs. Common causes of blood loss through the AV ﬁstula
in ESRD patients are also reviewed in the discussion part.
2.Case
A 57-year-old Caucasian man with a past medical history of
benign essential hypertension, dyslipidemia, coronary artery
disease status post1 coronary artery bypass grafting, systolic
congestive heart failure secondary to ischemic cardiomyopa-
thy, type 1 diabetes mellitus with associated complications
of diabetic retinopathy, neuropathy and nephropathy, h/o
ischemic stroke,HumanImmunodeﬁciencyVirus (HIV)posi-
tivitysince1992,andend-stagerenaldisease onhemodialysis
througharight armbrachiocephalicAVﬁstula(AVF)created
approximately ﬁve years ago presented to the emergency
room (ER) with bleeding from his AVF. He started having
problems with this AV ﬁstula almost a year previously
when he underwent an AV ﬁstulogram due to decreased
dialysis clearance. The ﬁstulogram identiﬁed two areas of
venousstenosis andananeurysmal dilatationintheproximal
portion of the outﬂow vein. No central vein stenosis was
seen. Successful angioplasty of the two sequential stenoses
was performed with establishment of good ﬁstula ﬂow.
Five months after this procedure, prolonged ﬁstula bleeding
after a routine dialysis led to another AV ﬁstulogram which
demonstrated a recurrent stenosis of the outﬂow tract in the
cephalic vein. Angioplasty was again successfully performed
with no visible residual stenosis on postoperative ﬁstulo-
gram. No routine access ﬂow monitoring was performed
in the dialysis unit. No signiﬁcant dialysis access issues
were observed until two weeks before the current presen-
tation when dialysis nurses observed aneurysmal dilatation
of his AV ﬁstula and recurrent prolonged bleeding from
the cannulation site. Vascular surgery appointment was
scheduled and pending. His home medications included
aspirin 81mg, clopidogrel 75mg, lamivudine, atazanavir,
lanthanum carbonate, carvedilol, amlodipine, valsartan,
levothyroxine, insulin aspart, and lantus. Of note, he was
on clopidogrel because of ischemic stroke while being on
aspirin. He was on a combination of both antiplatelets for
thelast4years.Onthedayofpresentation,anuncomplicated
hemodialysis treatment concluded at 11 AM and the patient2 International Journal of Nephrology
Figure 1: Right upper arm AV ﬁstula aneurysm of the patient. Size
is approximately 6 × 3cm.
drove himself home. About 30 minutes after his dialysis
treatment ended, he called a friend and complained of
bleeding from his AVF. The friend arrived half an hour later
and called 911. The patient was coherent and conscious but
complaining of generalized weakness, fatigue, and short-
ness of breath. Emergency medical services responded and
applied a pressure dressing to his AVF. Upon arrival in the
ER, his blood pressure was 117/98mmHg, pulse 79, and
regular, respiratory rate 18, temperature 98.6 F, SpO2 92%
onroomair.Hewaspaleandtherewasanareaofaneurysmal
dilatation of the right AVF with a pinpoint area of bleeding
which had largely stopped with pressure. Patient’s AVF is
shown in Figure 1. A short arm cast was on the right wrist
(wrist fracture had occurred three weeks earlier). There were
no obvious signs and symptoms of infection of the AVF and
no recent antibiotic use. Initial labs were remarkable for Hgb
6.7gm/dL and Hct of 21.8%. Of note, his hemoglobin the
prior month was 13.2gm/dL. His PTT, INR, and platelets
were normal. The patient was transfused 5 units of packed
red blood cells with appropriate response in hemoglobin.
Blood cultures remained negative. A tunneled catheter was
placed for hemodialysis access. A new left arm basilic vein
transposition AVF was created along with ligation of the
right brachiocephalic AVF. Three months later, the right
brachiocephalic ﬁstula was removed by vascular surgery;
intraoperatively a pseudoaneurysm and thrombosis of the
AV ﬁsula were observed. His hemoglobin six months after
discharge is stable at 12.5gm/dL.
3.Discussion
The Centers for Medicare and Medicaid Services Interpretive
Guidance Update requires every dialysis facility to have
an ongoing program for vascular access monitoring and
surveillance for early detection of failure and to allow timely
referral of patients for intervention. Physical examination
can be used as a monitoring tool to exclude low ﬂows
associated with impending vascular access failures. There are
3 components to the access examination: inspection (look),
Table 1: Causes of blood loss through AV ﬁstula.
Causes of blood loss through AV ﬁstula
(1) Aneurysm formation
(2) Stenosis and subsequent rupture
(3) Infection
(4) Trauma
(5) Use of anticoagulants and antiplatelets
(6) Suicide
palpation (touch), and auscultation (listen). Simple inspec-
tion can reveal the presence of aneurysms. A ﬁstula that does
not at least partially collapse with arm elevation is likely to
have an outﬂow stenosis. Strictures can be palpated and the
intensity and character of the bruits can suggest the location
of stenosis. Downstream stenosis also produces an overall
dilation of the vein, giving it “aneurysmal” proportions.
Observance of changes in adequacy or in pressures measured
during dialysis, diﬃculties in cannulation, or in achieving
hemostasis may also be used as monitoring tools [1–4].
Surveillance strategies include device-based methods
such as access ﬂow measurements, direct or derived static
venous pressure ratios, and duplex ultrasound, and so forth.
However, the proper role of surveillance awaits the results
of further research. The best available evidence indicates
that ﬁstula surveillance does not prolong ﬁstula life and
there is limited evidence that surveillance may reduce ﬁstula
thrombosis [4]. Serial monitoring of aneurysms may give
the opportunity to potentially prevent rupture by timely
intervention.
Evidence of periodic monitoring and surveillance of
the vascular access should be documented on the dialysis
treatment record, progress notes, or on a separate log. A
member of the facility staﬀ must review the vascular access
monitoring/surveillance documentation to identify adverse
trends and take action if indicated.
Our patient probably would have beneﬁted from early
vascularsurgicalinterventionbeforeanepisodeoflifethreat-
ening hemorrhage. He was on both aspirin and clopidogrel
although the current evidence suggests that the combined
use of aspirin and clopidogrel does not oﬀer greater beneﬁt
for stroke prevention than either agent alone but does
substantially increase the risk of bleeding complications [5].
Thus, it is likely that the antiplatelet agents contributed to
his bleeding and stopping the [6] dual antiplatelet therapy
should have been considered when aneurysmal dilation of
the ﬁstula was initially noticed.
The most common sources of acute access blood loss in
hemodialysis patients are shown in Table 1.T h e s ew i l lb e
brieﬂy reviewed.
3.1. Aneurysms. Aneurysms usually occur in long-lasting
arteriovenous ﬁstulas and form in areas of repeated needle
puncture sites [7]. Repeated needle punctures of the arte-
rialized veins over time result in destruction of the venous
wall and replacement by scar tissue causing loss of elasticity.
Subsequently, thinning of the vessel wall increases the riskInternational Journal of Nephrology 3
for rupture and bleeding [8]. There is also an increased risk
of bleeding each time after insertion and removal of dialysis
needles [9]. This is because the vessel wall is thinned in an
aneurysm and is easily injured and prone to bleeding and
rupture [10].
Cannulation should not be continued along any type of
aneurysm, particularly in patients for whom the skin layer
within the aneurysm is thin and prone to infection, a sign of
impending perforation [11].
Long-standing high blood ﬂow rates through an AV
ﬁstula results in shear forces that cause damage to the elastic
ﬁbers of the internal elastic lamina. The high ﬂow rates and
the resulting shear forces from repeated dialysis treatments
limit time for healing, thereby causing destruction of the
venous wall and aneurysm formation [12].
Arteriovenous ﬁstula aneurysms may be false aneurysms
or venous aneurysms [13]. False aneurysms are hematomas
located outside the vessel wall, formed due to a leaking hole
in the artery and are most often due to iatrogenic trauma,
primarily repeated needle punctures. Infection of a false
aneurysm increases the risk of rupture and bleeding as the
vessel wall is already thin.
Risk for bleeding and hematoma formation is greatest in
theearly stagesof useofa ﬁstulaand greaterin brachiobasilic
ﬁstulae than ﬁstulae at the wrist or elbow [11]. Venous
aneurysms occur when repeated trauma to the venous wall
is coupled with complete stenosis. The increased venous
resistance leads to progressive enlargement of the venous
aneurysm, thus increasing the risk of rupture [13]. True
aneurysms are fusiform, develop slowly over several years,
and lie beneath intact, nonulcerated skin making them less
prone to infection and rupture. On the contrary, pseudoa-
neurysms are usuallysaccular withthinning of overlyingskin
and develop over a short period of time, making them more
prone to rupture and infection [14]. Aneurysms are at risk
for rupture if they are large and rapidly expanding, if there
is thinning of overlying skin exposing the underlying ﬁstula
and if there are signs of local infection [15, 16].
The occurrence of large aneurysms, in addition to
threatening the function of the AVF, may ultimately rupture
with catastrophic sequelae. However surgical options to
repairsuchlargeaneurysms arelimitedandofteninvolveloss
ofthe AVF. Endovascularprocedures such as angioplasty and
stenting have been increasingly used to treat vascular access
dysfunction and to prolong the life of an AVF [17].
3.2. Stenosis. Venous stenosis within the perianastomotic
region is the leading cause of vascular access dysfunction
[18]. The basic underlying mechanism of venous stenosis is
neointimal hyperplasia due to cytokine production, cellular
proliferation, and microvessel formation [19]. This is trig-
gered by high intraluminal pressure, turbulent blood ﬂow,
vascular calciﬁcation, endothelial injury, and increased levels
of ﬁbronectin [20, 21]. Developmentof stenosis of AV ﬁstula
is also inﬂuenced by venous capacitance, surgical technique,
and the site of the AV ﬁstula.
In hemodialysis patients, a native AV ﬁstula is the
vascular access of choice owing to its superior patency and
low complication rates. Venous stenosis per se does not lead
to blood loss but can be complicated by aneurysm formation
with subsequent rupture and blood loss.
Aneurysms are observedwithin theﬁrst postanastomotic
venous segment in the presence of a hemodynamically
relevant stenosis in the juxta-anastomotic position The
therapy of choice is a new AV anastomosis using a healthy
venous segment located a few centimeters more proximally,
butasclosetotheformeranastomosisaspossible,topreserve
the maximum area for cannulation.
3.3. Infections. Vascular access site infection is considered to
be the most challenging complication and the major cause
of morbidity and mortality among chronic hemodialysis
patients [22]. It is also an important cause for AV ﬁstula
failure. The source of sepsis in the dialysis population is
largelyrelatedtovascularaccess.Infectionrateishighestwith
temporary central vein catheter followed by tunneled central
vein catheter and prosthetic AV grafts and is least with pri-
mary AV ﬁstulas [23–27]. Common factors associated with
increased AVF and AV graft infection include prior episode
of bacteremia, immunosuppression, poor personal hygiene,
poor aseptic techniques during cannulation, repeated can-
nulations, defects in neointimal lining, nasal staphylococcus
aureus carriage, diabetes mellitus, uremia, and age of ﬁstula
[22, 28]. Blood loss due to infections of AV ﬁstulas results
from vessel wall weakening leading to aneurysm formation
andrupture.Preexistinganeurysmscanrupturesecondaryto
superimposed infections. Surgical debridement of localized
infections can also result in signiﬁcant blood loss. Utilization
of antibacterial soap followed by either 70% alcohol or
10% povidone iodine has been shown to reduce the risk of
infections from needle cannulations [9]. A study showed a
slightly greater incidence of AV ﬁstula infections with the
button hole technique for cannulation when compared with
the rope ladder technique [29]. Recognizing and correcting
the modiﬁable risk factors for infection will help minimize
the incidence of AV ﬁstula infection and thereby decrease the
risk of access blood loss due to aneurysm rupture.
3.4. Trauma. The most common trauma to AV ﬁstulas
is repeated needle cannulations during dialysis. Dialysis
technicians and patients are taught to rotate needle insertion
sites during each dialysis. Proper cannulation is a vital
and fundamental skill that every hemodialysis nurse should
master. First cannulation should be carried out by nurses
who have great expertise [11, 30].
To reduce the bleeding time after needle withdrawal, all
superﬁcial AV ﬁstulas should be cannulated at an angle of
25 degrees [31]. There are 3 diﬀerentcannulation techniques
which include rope ladder, button hole, and area puncture.
In the rope ladder technique, puncture sites are spread
along the length of the vascular access, starting distally, and
proceeding proximally. This is the most popular method.
The button hole technique consists of puncturing the same
site, in the same direction and at the same angle and depth.
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and once a tract is formed, blunt needles are used. The
area puncture technique involves needle insertion within a
limited area of the ﬁstula. This technique is associated with
more complications such as aneurysm formation, thinning
of the skin at puncture sites, increased risk of bleeding along
theneedles,andlongerbleedingtimeafterneedlewithdrawal
[31].
A standard part of patient teaching should be on man-
aging interdialytic bleeding that includescompression with a
clean cloth and calling the dialysis facility for instructions.
They should also be instructed to go to the Emergency
Room or call 911 for a more severe, uncontrollable bleed. All
patientsshould betaughttocompressableedingaccess,wash
skinoveraccesswithsoap andwaterdailyandbeforedialysis,
and also recognize signs and symptoms of infection. All
patients should know to avoid carrying heavy items draped
over the access arm, avoid wearing occlusive clothing, wear
protective clothing over the exposed ﬁstula vein if working
around machinery or sharp tools [11].
3.5. Use of Antiplatelets, Anticoagulants, and Bleeding Ten-
dencies. Platelet biochemical abnormalities in ADP and
serotonin compounds along with thromboxane A2 leading
to defective platelet aggregation may contribute to increased
bleeding tendencies in dialysis patients [32, 33]. Platelet
numbers are usually not low enough to cause increased
bleeding [34]. Factor 8 and Von Willebrand factor alteration
may also play a crucial role as can anemia by leading to
defective platelet aggregation as demonstrated by in vitro
studies [35, 36]. Hemodialysis improves these hemostatic
complications but use of heparin during dialysis may be a
contributory factor to increased bleeding tendencies from
dialysis access sites including petechial hemorrhages, blood
blisters, ecchymosis, and hematoma. It is unusual for acute
accessblood loss tooccurdueto an underlying coagulopathy
though theoretically it may prolong bleeding from any other
reason.
Antiplatelet agents, such as dipyridamole and low-
dose aspirin with or without sulﬁnpyrazone, aspirin plus
clopidogrel, have been studied in an eﬀort to decrease graft
thrombosis but conﬂicting evidence exists in this regard and
no real recommendations exist for the use of antiplatelet
agents to prevent graft thrombosis [37, 38]. In one clinical
trial, role of aspirin plus clopidogrel versus double placebos
was studied in preventing graft thrombosis [39], but the
study was stopped because of a markedly increased risk of
bleeding among those receiving active therapy (hazard ratio
of 1.98, 95% CI 1.19–3.28). At study end, dual antiplatelet
therapy was not associated with a signiﬁcant beneﬁt in
preventing thrombosis. Similarly, administration of warfarin
does not increase graft survival and is associated with
signiﬁcant bleeding [40].
3.6. Suicide. The incidence and prevalence of depression
among dialysis patients is unknown but estimates vary from
20 to 50 percent [41]. Approximately one-fourth of dialysis
patients are depressed at some point in time. Furthermore,
about 1 percent of the dialysis patients commit suicide,
especially theelderlypopulation[42].Risk factorsfor suicide
include male gender, a preexistent psychiatric diagnosis, and
addiction to drugs or alcohol [43–45]. Bleeding from a
vascular access is rarely a result of a suicide attempt.
4.Conclusion
In summary, patients with ESRD may lose blood from the
AV ﬁstula due to a variety of reasons. Aneurysms should be
considered a risk factor for acute vascular access bleeding in
chronic dialysis patients and should never be cannulated. If
assessed to be at risk for rupture, a workup for associated
access infection should be considered and a surgical consult
for aneurysm repair initiated. Dual antiplatelet therapy
should be avoided in patients with AV ﬁstula aneurysms.
Patient education is important to avoid complications of
access bleeding; patients should be taught simple techniques
like putting direct pressure to minimize bleeding while
seeking acute medical care. Our patient should have applied
direct pressure to his AV ﬁstula and called for emergency
services, thus potentially reducing the duration of his
hospitalization.
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